TY  - JOUR
AU  - Rašić, Jelena
AU  - Ivanović, Nevena
AU  - Anđelković, Marija
AU  - Nedeljković, Ivana
AU  - Nikolić, Ivan
AU  - Stojanović, Sava
AU  - Ristić-Medić, Danijela
AU  - Takić, Marija
AU  - Đorđević, Brižta
AU  - Dikić, Nenad
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3972
AB  - The aim of this study was to determine the ergogenic effects and the safety profile of a one-component higenamine supplement in female recreational athletes. Twelve recreational female basketball players (age 29–41 years, oxygen consumption (VO2max) > 30 ml⋅kg–1⋅min–1, with training > 5 h wk–1) were randomized either to the higenamine group, or to the placebo group for 3 weeks. In order to determine ergogenic effects and safety profile of higenamine administration, we assessed the following variables before and after 3 weeks of supplementation: anthropometric parameters, resting metabolic rate (RMR), exercise testing variables, serum free fatty acids (FFAs), blood pressure, enzyme activity, urea, lipid profile, and complete blood count. There were no differences between groups in anthropometric parameters, including basal metabolic rate (BMR), RMR and body fat [p = 0.706 (Cohen’s d 0.223), p = 0.169 (Cohen’s d 0.857), and p = 0.223 (Cohen’s d 0.750), respectively], FFAs [0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)], neither significant differences in cardiopulmonary parameters after the intervention period. Furthermore, all measured outcome variables in the safety assessment were not significant, with values remaining stable during the intervention period for participants in both groups. This is the first study to document the effects and the safety profile of higenamine-based dietary supplements at a specified dose in female recreational athletes. Our data indicate that 21-day of supplementation with 75 mg higenamine would not result in improving cardiopulmonary exercise fitness and weight loss in female recreational athletes. Moreover, supplementation with 75 mg higenamine is safe and well-tolerated in younger recreational female athletes.
PB  - Frontiers Media S.A.
T2  - Frontiers in Psychology
T1  - Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial
VL  - 12
DO  - 10.3389/fpsyg.2021.633110
ER  - 

@article{
author = "Rašić, Jelena and Ivanović, Nevena and Anđelković, Marija and Nedeljković, Ivana and Nikolić, Ivan and Stojanović, Sava and Ristić-Medić, Danijela and Takić, Marija and Đorđević, Brižta and Dikić, Nenad",
year = "2021",
abstract = "The aim of this study was to determine the ergogenic effects and the safety profile of a one-component higenamine supplement in female recreational athletes. Twelve recreational female basketball players (age 29–41 years, oxygen consumption (VO2max) > 30 ml⋅kg–1⋅min–1, with training > 5 h wk–1) were randomized either to the higenamine group, or to the placebo group for 3 weeks. In order to determine ergogenic effects and safety profile of higenamine administration, we assessed the following variables before and after 3 weeks of supplementation: anthropometric parameters, resting metabolic rate (RMR), exercise testing variables, serum free fatty acids (FFAs), blood pressure, enzyme activity, urea, lipid profile, and complete blood count. There were no differences between groups in anthropometric parameters, including basal metabolic rate (BMR), RMR and body fat [p = 0.706 (Cohen’s d 0.223), p = 0.169 (Cohen’s d 0.857), and p = 0.223 (Cohen’s d 0.750), respectively], FFAs [0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)], neither significant differences in cardiopulmonary parameters after the intervention period. Furthermore, all measured outcome variables in the safety assessment were not significant, with values remaining stable during the intervention period for participants in both groups. This is the first study to document the effects and the safety profile of higenamine-based dietary supplements at a specified dose in female recreational athletes. Our data indicate that 21-day of supplementation with 75 mg higenamine would not result in improving cardiopulmonary exercise fitness and weight loss in female recreational athletes. Moreover, supplementation with 75 mg higenamine is safe and well-tolerated in younger recreational female athletes.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Psychology",
title = "Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial",
volume = "12",
doi = "10.3389/fpsyg.2021.633110"
}

Rašić, J., Ivanović, N., Anđelković, M., Nedeljković, I., Nikolić, I., Stojanović, S., Ristić-Medić, D., Takić, M., Đorđević, B.,& Dikić, N.. (2021). Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial. in Frontiers in Psychology
Frontiers Media S.A.., 12.
https://doi.org/10.3389/fpsyg.2021.633110

Rašić J, Ivanović N, Anđelković M, Nedeljković I, Nikolić I, Stojanović S, Ristić-Medić D, Takić M, Đorđević B, Dikić N. Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial. in Frontiers in Psychology. 2021;12.
doi:10.3389/fpsyg.2021.633110 .

Rašić, Jelena, Ivanović, Nevena, Anđelković, Marija, Nedeljković, Ivana, Nikolić, Ivan, Stojanović, Sava, Ristić-Medić, Danijela, Takić, Marija, Đorđević, Brižta, Dikić, Nenad, "Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial" in Frontiers in Psychology, 12 (2021),
https://doi.org/10.3389/fpsyg.2021.633110 . .

TY  - JOUR
AU  - Petrović, Milan
AU  - Petrović, Marija
AU  - Milasinović, Goran
AU  - Vujisić-Tesić, Bosiljka
AU  - Trifunović, Danijela
AU  - Petrović, Olga
AU  - Nedeljković, Ivana
AU  - Petrović, Ivana
AU  - Banović, Marko
AU  - Boricić-Kostić, Marija
AU  - Petrović, Jelena
AU  - Arena, Ross
AU  - Popović, Dejana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2918
AB  - Aims: Selection of patients who are viable candidates for cardiac resynchronization therapy (CRT), prediction of the response to CRT as well as an optimal definition of a favorable response, all require further exploration. The purpose of this study was to evaluate the interplay between the prediction of the response to CRT and the definition of a favorable outcome. Methods: Seventy patients who received CRT were included. All patients met current guideline criteria for CRT. Forty-three echocardiographic parameters were evaluated before CRT and at 1, 3, 6, and 12 months. M-mode, 2D echocardiography, and Doppler imaging were used to quantify left ventricular (LV) systolic and diastolic function, mitral regurgitation, right ventricular systolic function, pulmonary artery pressure, and myocardial mechanical dyssynchrony. The following definitions of a favorable CRT response were used: left ventricular ejection fraction (LVEF) improvement more >5% acutely following CRT, LVEF improvement >20% at 12-month follow-up, and a LV end-systolic volume (LVESV) decrease >15% at 12-month follow-up. Results: For the LVEF improvement >5%, the best predictor was isovolumetric relaxation time (IVRT; P=.035). For improvement of LVEF >20%, the best predictors were left ventricular stroke index (LVSI; P=.044) and left ventricular fractional shortening (LVFS; P=.031). For the drop in left ventricular systolic volume (LVESV >15%), the best predictor was septal-to-lateral wall delay (Delta T) (P=.043, RR=1.023, 95% CI for RR=1.001-1.045). Conclusion: The definition of a favorable CRT response influenced the optimal predictor variable(s). Standardization of defining a favorable response to CRT is needed to guide clinical decision making processes.
PB  - Wiley, Hoboken
T2  - Echocardiography-A Journal of Cardiovascular Ultrasound and Allied Techniques
T1  - Gauging the response to cardiac resynchronization therapy: The important interplay between predictor variables and definition of a favorable outcome
VL  - 34
IS  - 3
SP  - 371
EP  - 375
DO  - 10.1111/echo.13453
ER  - 

@article{
author = "Petrović, Milan and Petrović, Marija and Milasinović, Goran and Vujisić-Tesić, Bosiljka and Trifunović, Danijela and Petrović, Olga and Nedeljković, Ivana and Petrović, Ivana and Banović, Marko and Boricić-Kostić, Marija and Petrović, Jelena and Arena, Ross and Popović, Dejana",
year = "2017",
abstract = "Aims: Selection of patients who are viable candidates for cardiac resynchronization therapy (CRT), prediction of the response to CRT as well as an optimal definition of a favorable response, all require further exploration. The purpose of this study was to evaluate the interplay between the prediction of the response to CRT and the definition of a favorable outcome. Methods: Seventy patients who received CRT were included. All patients met current guideline criteria for CRT. Forty-three echocardiographic parameters were evaluated before CRT and at 1, 3, 6, and 12 months. M-mode, 2D echocardiography, and Doppler imaging were used to quantify left ventricular (LV) systolic and diastolic function, mitral regurgitation, right ventricular systolic function, pulmonary artery pressure, and myocardial mechanical dyssynchrony. The following definitions of a favorable CRT response were used: left ventricular ejection fraction (LVEF) improvement more >5% acutely following CRT, LVEF improvement >20% at 12-month follow-up, and a LV end-systolic volume (LVESV) decrease >15% at 12-month follow-up. Results: For the LVEF improvement >5%, the best predictor was isovolumetric relaxation time (IVRT; P=.035). For improvement of LVEF >20%, the best predictors were left ventricular stroke index (LVSI; P=.044) and left ventricular fractional shortening (LVFS; P=.031). For the drop in left ventricular systolic volume (LVESV >15%), the best predictor was septal-to-lateral wall delay (Delta T) (P=.043, RR=1.023, 95% CI for RR=1.001-1.045). Conclusion: The definition of a favorable CRT response influenced the optimal predictor variable(s). Standardization of defining a favorable response to CRT is needed to guide clinical decision making processes.",
publisher = "Wiley, Hoboken",
journal = "Echocardiography-A Journal of Cardiovascular Ultrasound and Allied Techniques",
title = "Gauging the response to cardiac resynchronization therapy: The important interplay between predictor variables and definition of a favorable outcome",
volume = "34",
number = "3",
pages = "371-375",
doi = "10.1111/echo.13453"
}

Petrović, M., Petrović, M., Milasinović, G., Vujisić-Tesić, B., Trifunović, D., Petrović, O., Nedeljković, I., Petrović, I., Banović, M., Boricić-Kostić, M., Petrović, J., Arena, R.,& Popović, D.. (2017). Gauging the response to cardiac resynchronization therapy: The important interplay between predictor variables and definition of a favorable outcome. in Echocardiography-A Journal of Cardiovascular Ultrasound and Allied Techniques
Wiley, Hoboken., 34(3), 371-375.
https://doi.org/10.1111/echo.13453

Petrović M, Petrović M, Milasinović G, Vujisić-Tesić B, Trifunović D, Petrović O, Nedeljković I, Petrović I, Banović M, Boricić-Kostić M, Petrović J, Arena R, Popović D. Gauging the response to cardiac resynchronization therapy: The important interplay between predictor variables and definition of a favorable outcome. in Echocardiography-A Journal of Cardiovascular Ultrasound and Allied Techniques. 2017;34(3):371-375.
doi:10.1111/echo.13453 .

Petrović, Milan, Petrović, Marija, Milasinović, Goran, Vujisić-Tesić, Bosiljka, Trifunović, Danijela, Petrović, Olga, Nedeljković, Ivana, Petrović, Ivana, Banović, Marko, Boricić-Kostić, Marija, Petrović, Jelena, Arena, Ross, Popović, Dejana, "Gauging the response to cardiac resynchronization therapy: The important interplay between predictor variables and definition of a favorable outcome" in Echocardiography-A Journal of Cardiovascular Ultrasound and Allied Techniques, 34, no. 3 (2017):371-375,
https://doi.org/10.1111/echo.13453 . .

TY  - JOUR
AU  - Dobrić, Milan
AU  - Giga, Vojislav
AU  - Beleslin, Branko
AU  - Ignjatović, Svetlana
AU  - Paunović, Ivana
AU  - Stepanović, Jelena M.
AU  - Đorđević-Dikić, Ana
AU  - Kostić, Jelena
AU  - Nedeljković, Ivana
AU  - Nedeljković, Milan
AU  - Tesić, Milorad
AU  - Dajak, Marijana
AU  - Ostojić, Miodrag
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1868
AB  - Background: Glycogen phosphorylase BB (GPBB) is released from cardiac cells during myocyte damage. Previous studies have shown contradictory results regarding the relation of enzyme release and reversible myocardial ischemia. The aim of this study was to determine the plasma kinetics of GPBB as a response to the exercise stress echocardiographic test (ESET), and to define the relationship between myocardial ischemia and enzyme plasma concentrations. Methods: We studied 46 consecutive patients undergoing ESET, with recent coronary angiography. In all patients, a submaximal stress echo test according to Bruce protocol was performed. Concentration of GPBB was measured in peripheral blood that was sampled 5 min before and 10, 30 and 60 min after ESET. Results: There was significant increase of GPBB concentration after the test (p=0.021). Significant increase was detected 30 min (34.9% increase, p=0.021) and 60 min (34.5% increase, p=0.016) after ESET. There was no significant effect of myocardial ischemia on GPBB concentrations (p=0.126), and no significant interaction between sampling intervals and myocardial ischemia, suggesting a similar release profile of GPBB in ischemic and non-ischemic conditions (p=0.558). Patients in whom ESET was terminated later (stages 4 or 5 of standard Bruce protocol; n=13) had higher GPBB concentrations than patients who terminated ESET earlier (stages 1, 2 or 3; n=33) (p=0.049). Baseline GPBB concentration was not correlated to any of the patients' demographic, clinical and hemodynamic characteristics. Conclusions: GPBB plasma concentration increases after ESET, and it is not related to inducible myocardial ischemia. However, it seems that GPBB release during ESET might be related to exercise load/duration.
PB  - Walter de Gruyter Gmbh, Berlin
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test
VL  - 51
IS  - 10
SP  - 2029
EP  - 2035
DO  - 10.1515/cclm-2013-0109
ER  - 

@article{
author = "Dobrić, Milan and Giga, Vojislav and Beleslin, Branko and Ignjatović, Svetlana and Paunović, Ivana and Stepanović, Jelena M. and Đorđević-Dikić, Ana and Kostić, Jelena and Nedeljković, Ivana and Nedeljković, Milan and Tesić, Milorad and Dajak, Marijana and Ostojić, Miodrag",
year = "2013",
abstract = "Background: Glycogen phosphorylase BB (GPBB) is released from cardiac cells during myocyte damage. Previous studies have shown contradictory results regarding the relation of enzyme release and reversible myocardial ischemia. The aim of this study was to determine the plasma kinetics of GPBB as a response to the exercise stress echocardiographic test (ESET), and to define the relationship between myocardial ischemia and enzyme plasma concentrations. Methods: We studied 46 consecutive patients undergoing ESET, with recent coronary angiography. In all patients, a submaximal stress echo test according to Bruce protocol was performed. Concentration of GPBB was measured in peripheral blood that was sampled 5 min before and 10, 30 and 60 min after ESET. Results: There was significant increase of GPBB concentration after the test (p=0.021). Significant increase was detected 30 min (34.9% increase, p=0.021) and 60 min (34.5% increase, p=0.016) after ESET. There was no significant effect of myocardial ischemia on GPBB concentrations (p=0.126), and no significant interaction between sampling intervals and myocardial ischemia, suggesting a similar release profile of GPBB in ischemic and non-ischemic conditions (p=0.558). Patients in whom ESET was terminated later (stages 4 or 5 of standard Bruce protocol; n=13) had higher GPBB concentrations than patients who terminated ESET earlier (stages 1, 2 or 3; n=33) (p=0.049). Baseline GPBB concentration was not correlated to any of the patients' demographic, clinical and hemodynamic characteristics. Conclusions: GPBB plasma concentration increases after ESET, and it is not related to inducible myocardial ischemia. However, it seems that GPBB release during ESET might be related to exercise load/duration.",
publisher = "Walter de Gruyter Gmbh, Berlin",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test",
volume = "51",
number = "10",
pages = "2029-2035",
doi = "10.1515/cclm-2013-0109"
}

Dobrić, M., Giga, V., Beleslin, B., Ignjatović, S., Paunović, I., Stepanović, J. M., Đorđević-Dikić, A., Kostić, J., Nedeljković, I., Nedeljković, M., Tesić, M., Dajak, M.,& Ostojić, M.. (2013). Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test. in Clinical Chemistry and Laboratory Medicine
Walter de Gruyter Gmbh, Berlin., 51(10), 2029-2035.
https://doi.org/10.1515/cclm-2013-0109

Dobrić M, Giga V, Beleslin B, Ignjatović S, Paunović I, Stepanović JM, Đorđević-Dikić A, Kostić J, Nedeljković I, Nedeljković M, Tesić M, Dajak M, Ostojić M. Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test. in Clinical Chemistry and Laboratory Medicine. 2013;51(10):2029-2035.
doi:10.1515/cclm-2013-0109 .

Dobrić, Milan, Giga, Vojislav, Beleslin, Branko, Ignjatović, Svetlana, Paunović, Ivana, Stepanović, Jelena M., Đorđević-Dikić, Ana, Kostić, Jelena, Nedeljković, Ivana, Nedeljković, Milan, Tesić, Milorad, Dajak, Marijana, Ostojić, Miodrag, "Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test" in Clinical Chemistry and Laboratory Medicine, 51, no. 10 (2013):2029-2035,
https://doi.org/10.1515/cclm-2013-0109 . .